Valuation: Lundbeck

Market Cap 4.04TCr 615.55Cr 539.9Cr 500.05Cr 460.1Cr 870.26Cr 59TCr 887.2Cr 5.96TCr 2.34TCr 29TCr 2.31TCr 2.26TCr 1LCr P/E 2026 *
9.16x
P/E 2027 * 9.11x
Enterprise Value 4.45TCr 677.9Cr 594.58Cr 550.7Cr 506.7Cr 958.4Cr 65TCr 977.05Cr 6.56TCr 2.57TCr 32TCr 2.55TCr 2.49TCr 1,10000Cr EV / Sales 2026 *
1.72x
EV / Sales 2027 * 1.56x
Free-Float
30.76%
Yield 2026 *
3.59%
Yield 2027 * 3.67%
1 day-2.46%
1 week-1.22%
Current month-0.18%
1 month-2.65%
3 months+5.57%
6 months-3.40%
Current year-1.47%
1 week 5.59
Extreme 5.59
5.82
1 month 5.54
Extreme 5.545
5.92
Current year 4.85
Extreme 4.852
6.26
1 year 4.48
Extreme 4.476
6.4
3 years 3.67
Extreme 3.666
6.62
5 years 3.26
Extreme 3.259
8.85
10 years 3.26
Extreme 3.259
8.85
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.46%-1.22% - - 615.55Cr
-0.68%+0.15%+12.99%+97.45% 9.51TCr
-1.31%-3.70%+42.76%+147.84% 5.47TCr
0.00%+3.55%+2.10%+269.62% 2.33TCr
+1.24%-0.73%-14.05%-22.61% 809.78Cr
+2.67%-1.64%-25.39%-33.86% 754.21Cr
+0.95%-1.33%-9.71%-27.31% 670.85Cr
-0.37%+0.52%-2.08%+22.42% 536.36Cr
+1.00%+0.20%-5.24%-6.75% 372.12Cr
+0.51%-0.96%+12.82%+17.15% 335.57Cr
Average +0.16%+1.17%+1.58%+51.55% 2.31TCr
Weighted average by Cap. -0.52%+1.84%+15.71%+111.45%

Financials

2026 *2027 *
Net sales 2.58TCr 393.28Cr 344.95Cr 319.49Cr 293.96Cr 556.02Cr 38TCr 566.84Cr 3.81TCr 1.49TCr 18TCr 1.48TCr 1.44TCr 64TCr 2.59TCr 394.44Cr 345.96Cr 320.43Cr 294.83Cr 557.66Cr 38TCr 568.51Cr 3.82TCr 1.5TCr 19TCr 1.48TCr 1.45TCr 64TCr
Net income 455.29Cr 69Cr 61Cr 56Cr 52Cr 98Cr 6.65TCr 100.07Cr 672.22Cr 263.65Cr 3.26TCr 260.71Cr 255.01Cr 11TCr 459.68Cr 70Cr 61Cr 57Cr 52Cr 99Cr 6.71TCr 101.03Cr 678.71Cr 266.19Cr 3.29TCr 263.23Cr 257.47Cr 11TCr
Net Debt 408.83Cr 62Cr 55Cr 51Cr 47Cr 88Cr 5.97TCr 90Cr 603.62Cr 236.74Cr 2.93TCr 234.11Cr 228.99Cr 10TCr -4.41Cr -67.3L -59.03L -54.67L -50.31L -95.15L -64Cr -97L -6.52Cr -2.56Cr -32Cr -2.53Cr -2.47Cr -109.25Cr
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
10/26/10 5.690 -1.13%
13/26/13 €5.595 -1.67%
10/26/10 €5.690 -1.13%
09/26/09 €5.755 -0.95%
08/26/08 €5.810 -0.68%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
41.82DKK
Average target price
47.62DKK
Spread / Average Target
+13.88%

Quarterly revenue - Rate of surprise